STAT Inhibitors - Pipeline Insight, 2022

January 2022 | 90 pages | ID: S1DBB20BC6F0EN
DelveInsight

Abstracts

This report can be delivered to the clients within 2-3 working days

DelveInsight’s, “STAT Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in STAT Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

STAT Inhibitors Understanding

STAT Inhibitors: Overview

Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. Signal transducer and activator of transcription (STAT) proteins represent novel therapeutic targets for the treatment of cancer. In particular, STAT?3 serves critical roles in several cellular processes, including the cell cycle, cell proliferation, cellular apoptosis and tumorigenesis. Persistent activation of STAT?3 has been reported in a variety of cancer types, and a poor prognosis of cancer may be associated with the phosphorylation level of STAT?3. Furthermore, elevated STAT?3 activity has been demonstrated in a variety of mammalian cancers, both in vitro and in vivo. This indicates that STAT?3 serves an important role in the progression of numerous cancer types. A significant obstacle in developing STAT?3 inhibitors is the demonstration of the antitumor efficacy in in vivo systems and the lack of animal models for human tumors.

'STAT Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the STAT Inhibitors pipeline landscape is provided which includes the disease overview and STAT Inhibitors treatment guidelines. The assessment part of the report embraces, in depth STAT Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, STAT Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve STAT Inhibitors.

STAT Inhibitors Emerging Drugs Chapters

This segment of the STAT Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

STAT Inhibitors Emerging Drugs

• Bardoxolone methyl: Reata Pharmaceuticals

Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”). The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome. In April 2021, Reata Pharmaceuticals announced that the U.S. Food and Drug Administration (“FDA”) accepted for filing the New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.

• SHR-0302: Jiangsu Hengrui Medicine Co./ Reistone Biopharma

SHR0302 is a potent and highly selective Janus kinase type 1 (JAK1) inhibitor, STAT3 transcription factor inhibitors and was in-licensed by Reistone from Jiangsu Hengrui Medicine Co., Ltd. Several late stage clinical studies are on-going with both oral and topical dosage forms for several immune-inflammatory diseases including Ulcerative Colitis, Crohn's disease, etc. The high selectivity of SHR0302 may potentially provide a favorable safety and efficacy profile compared to the pan-JAK inhibitors.

Further product details are provided in the report……..

STAT Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in STAT Inhibitors

There are approx. 25+ key companies which are developing the therapies for STAT Inhibitors. The companies which have their STAT Inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, Reata Pharmaceuticals.

• Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

STAT Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

STAT Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses STAT Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging STAT Inhibitors drugs.

STAT Inhibitors Report Insights

• STAT Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

STAT Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing STAT Inhibitors drugs?
• How many STAT Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of STAT Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the STAT Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for STAT Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bio-Path Holdings
• Jiangsu Hengrui Medicine Co.
• Reata Pharmaceuticals
• Tvardi Therapeutics
• Purple Biotech

Key Products

• BP-1003
• SHR-0302
• Bardoxolone methyl
• TTI-101
• TTI-102
• NT-219

Contents

Introduction
Executive Summary
STAT Inhibitors: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
  Comparative Analysis
SHR-0302: Jiangsu Hengrui Medicine Co.
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Drug Name: Company Name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
  Comparative Analysis
TTI-101: Tvardi Therapeutics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
  Comparative Analysis
TTI-102: Tvardi Therapeutics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
STAT Inhibitors Key Companies
STAT Inhibitors Key Products
STAT Inhibitors- Unmet Needs
STAT Inhibitors- Market Drivers and Barriers
STAT Inhibitors- Future Perspectives and Conclusion
STAT Inhibitors Analyst Views
STAT Inhibitors Key Companies
Appendix